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ORIGINAL ARTICLE
pH-sensitive pHLIPVR coated niosomes
Mohan C. Pereiraa, Monica Pianellab, Da Weia, Anna Moshnikovaa, Carlotta Marianeccib, Maria Carafab,
Oleg A. Andreeva and Yana K. Reshetnyaka
aPhysics Department, University of Rhode Island, Kingston, RI, USA; bDipartimento di Chimica e Tecnologie del Farmaco, Sapienza
Universita di Roma, Roma, Italia
ABSTRACT
Nanomedicine is becoming very popular over conventional methods due to the ability to tune
physico-chemical properties of nano vectors, which are used for encapsulation of therapeutic
and diagnostic agents. However, the success of nanomedicine primarily relies on how specifically
and efficiently nanocarriers can target pathological sites to minimize undesirable side effects and
enhance therapeutic efficacy. Here, we introduce a novel class of targeted nano drug delivery
system, which can be used as an effective nano-theranostic for cancer. We formulated pH-sensi-
tive niosomes (80–90nm in diameter) using nonionic surfactants Span20 (43–45mol%), choles-
terol (50mol%) and 5mol% of pH (Low) insertion peptide (pHLIP) conjugated with DSPE lipids
(DSPE-pHLIP) or hydrophobic fluorescent dye, pyrene, (Pyr-pHLIP). In coating of niosomes, pHLIP
was used as an acidity sensitive targeting moiety. We have demonstrated that pHLIP coated nio-
somes sense the extracellular acidity of cancerous cells. Intravenous injection of fluorescently
labeled (R18) pHLIP-coated niosomes into mice bearing tumors showed significant accumulation
in tumors with minimal targeting of kidney, liver and muscles. Tumor-targeting niosomes coated
with pHLIP exhibited 2–3 times higher tumor uptake compared to the non-targeted niosomes
coated with PEG polymer. Long circulation time and uniform bio-distribution throughout the
entire tumor make pHLIP-coated niosomes to be an attractive novel delivery system.
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Introduction
Most of the currently approved nano-medicinal prod-
ucts for cancer imaging and therapy are non-targeted
nano vectors that accumulate in the tumor tissues
purely through the enhanced permeability and reten-
tion (EPR) effect (Dawidczyk et al., 2014). It is nearly
impossible to find a universal targeting moiety for can-
cers as they are heterogeneous (Stingl & Caldas, 2007;
Weigelt et al., 2005). At the same time, extracellular
acidity has been identified as a general property of
cancerous cells and especially the most aggressive
ones (Calorini et al., 2012; Stubbs et al., 2000). Family
of pH (Low) insertion peptides (pHLIPVR peptides) are
under development as novel agents, which target
tumor acidity (Andreev et al., 2009: Weerakkody et al.,
2013). The peptides sense pH at the surface of cancer
cells, where it is the lowest (Anderson et al., 2016),
and enters into cellular membranes (Andreev et al.,
2010; Reshetnyak et al., 2006, 2007, 2008).
Nanocarriers decorated with pHLIPs are biocompatible,
can target tumor and demonstrate enhanced cellular
uptake by cancer cells (Arachchige et al., 2015; Du
et al., 2014; Wijesinghe et al., 2013; Yao et al.,
2013a,2013b). In addition to pHLIP-coated nanopar-
ticles, nanocarriers containing pH-sensitive polymers
and lipids were known for decades (Chu et al., 1990;
Karanth & Murthy, 2007; Lee et al., 1998; Subbarao
et al., 1987).
In this study we introduced pHLIP-coated niosomes.
Niosomes are self-assembled bilayer vesicles analogous
to liposomes, comprised of surfactants of SpanVR ,
TweenVR or BrijVR series (Rajera et al., 2011). Similar to
liposomes, niosomes are used to encapsulate both
hydrophilic and lipophilic drugs. At the same time,
nonionic surfactant vesicles, niosomes, are cheaper in
production, have longer shelf lives compared to lipo-
some and the bilayer fluidity and microviscosity could
be easily modulated (Karim et al., 2010; Lohumi, 2012;
Marianecci et al., 2014; Moghassemi & Hadjizadeh,
2014). Sorbitan esters (SpansVR ) are FDA approved for
use in food processing and pharmaceuticals (Cottrell &
van Peij, 2004). They are safe, amphiphilic compounds
derived from sorbitol (i.e., a synthetic sweetener).
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Span20 mostly consists of a fully saturated short alkyl
chain (lauryl – C12). The single carbon bonds in
Span20 allow the alkyl chain to pack tightly, resulting
in the smallest and stable niosomes, opposing the nio-
somes consisting of longer chain surfactants, Spans40-
80 (Hao et al., 2002; Israelachvili et al., 1980; Lo et al.,
2010). Vesicles prepared by Span-series surfactants
have been reported to be viable drug carriers for dif-
ferent diseases and different routes of administration
(Ammar et al., 2011; Balakrishnan et al., 2009;
Ghanbarzadeh et al., 2015; Guinedi et al., 2005; Hunter
et al., 1988; Jadon et al., 2009; Liu et al., 2017;
Pardakhty et al., 2007; Sahoo et al., 2014). In this study
we introduced novel formulations, pHLIP-coated nio-
somes, comprised of Span20 surfactant and
cholesterol.
Materials and methods
Materials
Sorbitan monolaurate (Span20); cholesterol 99%;
N-(2-Hydroxyethyl)piperazine-N0-(2-ethanesulfonic acid)
(HEPES) 99.5% and N-(1-Pyrenyl)maleimide (Pyr-
maleimide) were purchased from Sigma-Aldrich.
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[4-
(p-maleimidophenyl)butyramide] sodium salt (DSPE-
maleimide) and 1,2-distearoyl-sn-glycero-3-phosphoe-
thanolamine-N-[carboxy(polyethylene glycol)-2000]
ammonium salt (DSPE-PEG(2000)) were obtained from
Avanti Polar Lipids. Octadecyl Rhodamine B chloride
(R18) was purchased from Thermo Fisher Scientific.
The wild type (WT) pH (Low) Insertion Peptide:
ACEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT was
prepared by solid-phase peptide synthesis and purified
at the C.S. Bio. All other chemicals used in the study
were of the highest purity and all the solvents were of
spectroscopic grade. Water was purified through a
Millipore Milli-Q system.
Synthesis of DSPE-pHLIP and Pyr-pHLIP
pHLIP was conjugated with Pyr-maleimide or DSPE-
maleimide in methanol. 5mg of peptide dissolved in
250 lL methanol (blown with argon) and Pyr-malei-
mide or DSPE-maleimide (from 9.9mM stock solution)
dissolved in chloroform was mixed at a molar ratio 1:1.
The reaction mixture was kept at room temperature
for about 2–6 hours until the conjugation was com-
pleted. The Pyr-pHLIP product formation was moni-
tored by the reversed phase (Zorbax SB-C18 columns,
4.6 250mm 5 lm, Agilent Technology) high-perform-
ance liquid chromatography (RP-HPLC) using a
gradient from 25–75% acetonitrile in water containing
0.05% trifluoroacetic acid (TFA). The Pyr-pHLIP product
was characterized by SELDI-TOF mass spectrometry
(Pyr-pHLIP expected MW 4409.0 found 4401.7,
Figure S1). The concentration of Pyr-pHLIP conjugate
was determined by absorbance using the molar extinc-
tion coefficient for Pyr: E 3 3 9¼ 40,000 – M1 cm1. The
reaction progress in conjugation of DSPE with pHLIP
was monitored by the RP-HPLC using a gradient from
25–80% acetonitrile in water containing 0.05% TFA by
monitoring a decrease of peak corresponding to the
unlabeled pHLIP in the reaction mixture. The concen-
tration of DSPE-pHLIP conjugate was determined by
absorbance using the molar extinction coefficient for
pHLIP:E2 8 0¼ 13,940 M1 cm1.
Niosomes preparation
10mM stock solutions of Span20 and cholesterol were
prepared by dissolving the products in chloroform and
methanol mixture of 3:1 (v/v). pHLIP-coated niosomes
were prepared by mixing solutions of the 43mol% of
Span20, 50mol% of cholesterol, 5mol% of DSPE-pHLIP
or Pyr-pHLIP and 2mol% of R18. PEG-coated niosomes
were prepared by mixing solutions of the 43mol% of
Span20, 50mol% of cholesterol, 5mol% of DSPE-PEG
and 2mol% of R18. Some preparations of niosomes
used for fluorescence spectroscopy measurements,
hemolysis and plasma stability studies contained no
R18 and comprised of 45mol% of Span20, 50mol% of
cholesterol, 5mol% of Pyr-pHLIP, or DSPE-pHLIP, or
DSPE-PEG. Solutions containing all components were
evaporated in the flask covered with aluminum foil for
1 h on rotary evaporator at 60 C producing an even
thin film, followed by additional 1 h evaporation under
the high vacuum to remove traces of organic solvents.
The layers were hydrated in 2mL of p 10mM PBS or
HEPES buffer solutions, pH 7.4 containing 137mM
NaCl, 2.7mM KCl and 1mM CaCl2 in a preheated oven
at 60 C. To disrupt large particles and obtain mono-
disperse solution of nanoparticles we employed both
sonication and extrusion. The sonication and extrusion
protocols were optimized varying power and duration
of sonication, as well as adjusting extrusion approach.
According to the optimized protocol niosome solution
was sonicated using the probe sonicator VirTis
(VirSonic 100) for approximately 5minutes at 60 C
at output power of 8–10 Watts, followed by conse-
quential extrusion (31 times) using 200 , 100 and
50 nm filters. Niosome solution was sterilized by
filtering through a 0.2 lm filter. The concentration
was calculated by measuring absorbance of R18 at
546 nm (E 5 4 6¼ 104,126 – M1 cm1) or pHLIP at
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280 nm (E2 8 0¼ 13,940M1 cm1) of the niosomes dis-
solved in methanol and then the niosomes were
stored at 4 C.
Size and zeta potential measurements
The size distribution of niosomes was measured by
dynamic light scattering (DLS) using a Zetasizer
Nano ZS (Malvern) instrument and a nanoparticle
tracking system, Nanosight (NS300, Malvern). The zeta
(f) potential was measured on a Zetasizer Nano ZS
instrument using folded capillary cells from Malvern.
Fluorescence measurements
Steady-state fluorescence measurements were carried
out under a temperature control at 25 C on a PC1
spectrofluorometer (ISS, Inc.). The concentration of the
pyrene was 12.5 lM. Pyrene fluorescence was excited
at 333 nm and recorded in the range of 350–500 nm.
The polarizers in the excitation and emission paths
were set at the “magic” angle (54.7 from the vertical
orientation) and vertically (0), respectively.
Cryo-electron microscopy
Niosome solution (5lL droplet) was spread on a Lacey
formar/carbon electron microscopy grid and preserved
in a frozen-hydrated state by a rapid freezing in liquid
ethane. The vitrification process was performed using
FEI Vitrobot system with the setting of a single blot of
3 sec, an offset of 1 and drain and waiting time of
1 sec. Transmission electron microscopy (TEM) (JEOL
2100) with an accelerating voltage of 200 kV at magni-
fications in the range of 10,000 to 150,000 was used
to image niasomes to establish the shape, size and
homogeneity of the particles. Size histograms were fit-
ted with a Gauss function.
Cell lines
Lung carcinoma A549 and mouse mammary 4T1 cell
lines were obtained from American Type Culture
Collection (ATCC). Cells were authenticated, stored
according to the supplier’s instructions and used
within 3–4months after frozen aliquots resuscitations.
Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) and Roswell Park Memorial Institute
Medium (RPMI) supplemented with 10% fetal bovine
serum (FBS), 0.1% of 10 lg/mL of ciprofloxacin (Cipro)
in a humidified atmosphere of 5% CO2 and 95% air
at 37 C.
Cell proliferation assay
A549 and 4T1 cells were seeded in 96 well-plates
(3,000 cells per well) at pH 7.4. The following day,
cells were treated for 2 hours with increasing concen-
trations of pHLIP-coated niosomes (0, 10, 50, 100,
250, 500 and 1000 lM of Span20) in serum free
DMEM media at pH 7.4, followed by addition of an
equal volume of medium with 20% (v/v) FBS. In
another experiment, after 2 hours of cells treatment
with pHLIP-coated niosomes, the solution was
replaced by media containing 10% FBS. Cells were
grown for 3 days until non-treated cells in control
reached 80–90% confluence. Cell viability was
assessed by the colorimetric reagent (CellTiter 96
AqueousOne Solution Assay, Promega) of the MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay, which
was added for 1 hour to cells followed by measuring
absorbance at 490 nm. All samples were prepared
in triplicate. Each experiment was repeated several
times.
Hemolysis assay
Single donor human whole blood was purchased from
Innovative Research. Red blood cells (RBCs) were col-
lected by centrifugation of whole blood at 2000 rpm
for 10minutes followed by washing three times with
Dulbecco’s PBS (DPBS) and re-suspended in DPBS at a
concentration of 7.5% (v:v). Varying concentrations of
niosomes (from 50 up to 400 lM) in 10mM HEPES buf-
fer, pH 7.4 containing 137mM NaCl, 2.7mM KCl, 1mM
CaCl2 were added to RBCs to form 5% RBC suspension.
The resultant mixtures were incubated at 37 C for
2 hours and then centrifuged at 2000 rpm for 10min.
The hemolysis was assessed by the release of hemo-
globin, which was monitored by measuring of absorb-
ance at 450 nm. 10mM HEPES buffer, pH 7.4
containing 137mM NaCl, 2.7mM KCl, 1mM CaCl2 and
DPBS were used as negative controls. As positive con-
trols, which result in 100% lysis of RBCs: water and
10% of Triton X-100 was used. The percentage of hem-
olysis was calculated as follows:
% Hemolysis ¼ 100  ODTest  ODNC
ODPC  ODNC
where, ODTest, ODNC, and ODPC are the optical density
reading (absorbance) values of the test sample, nega-
tive control and positive control, respectively. The
assay was performed in triplicate on niosomes with
and without R18.
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Stability in plasma
Plasma was separated from the single donor human
whole blood by centrifugation of whole blood at
2000 rpm for 10minutes and collecting of supernatant.
Varying concentrations of niosomes (from 50 to
400 lM) in 10mM HEPES buffer, pH 7.4 containing
137mM NaCl, 2.7mM KCl, 1mM CaCl2 were added to
plasma and incubated at 37 C. The stability of nio-
somes was assessed by monitoring size of niosomes
measured using a nanoparticle tracking system,
Nanosight (NS300, Malvern) before mixing with plasma
and at 0, 2 and 24 hours after the treatment with
plasma.
Cellular uptake of niosomes
A549 and 4T1 cells (500,000 cells) in suspension were
treated with 500 lM R18 labeled pHLIP-coated nio-
somes at pH 7.8 and pH 5.5 for about 1 hour at 37 C in
serum free DMEM media. We used DMEM containing
no sodium bicarbonate and adjusted the pH by using
HCl or NaOH. After incubation period, cells were pel-
leted by centrifugation (2500 rpm, 2.5min) at room
temperature. The supernatant was removed and the
cell pellet was re-suspended in 1mL of fresh PBS of pH
7.4 and centrifuged for the second time. The second
cell pellet was re-suspended in PBS of pH 7.4 with or
without addition of Trypan Blue solution (Sigma-
Aldrich). The 20 lL of the cell suspension solution was
loaded into a counting chamber. The cellular uptake of
fluorescent niosomes was assessed by counting of
fluorescent cells using Nexcelom cellometer at 525 nm
excitation and 595 nm emission channels.
Fluorescence microscopy
In a separate experiment, A549 and 4T1 cells
(500,000 cells) in suspension were treated with
500 lM R18 labeled pHLIP-coated niosomes at pH 6.4
(or normal pH 7.4) for 1 hour at 37 C serum free
media and followed by the described above steps of
cell washing. After washing, the cell pellet was re-sus-
pended and cells were seeded in glass bottom colla-
gen coated cell dishes (MatTek). The phase contrast
and fluorescence images of the cells were recorded at
0, 4 and 24 hours under an inverted epi-fluorescence
microscope (Olympus IX71) using 20 and 40
objective lenses.
Tumor mouse model
All animal studies were conducted according to the
animal protocol AN07-01-015 approved by the
Institutional Animal Care and Use Committee at the
University of Rhode Island, in compliance with the
principles and procedures outlined by NIH for the Care
and Use of Animals. 4T1 mammary tumors were estab-
lished by subcutaneous injection of 4T1 cells (1 106
cells/mL, 0.1mL/flank) in the right flank of adult
female BALB/c mice (about 20–25 g weight) obtained
from Envigo RMS, Inc. For this study, 34 mice were
used including controls.
Ex vivo fluorescence imaging
When tumors reached 6–8mm in diameter different
constructs of niosomes containing 2mol% of fluores-
cent R18 were given as a single tail vein injection
(100 lL of 50lM of R18). Animals were euthanized at
4, 24 and 48 hours post-injection. Necropsy was
performed immediately after euthanization. The
Supplementary Tables S1 and S2 contain information
about the number of animals used for each fluores-
cently-labeled niosomes for each time point. Tumors,
kidneys, liver and muscles were collected for imaging
on a FX Kodak invivo image station connected to the
Andor CCD. The imaging was performed using excita-
tion and emission filters with a band of transmittance
at 540 ± 20 and 605± 20 nm, respectively. The mean
fluorescence intensities of tumor and organs were cal-
culated using ImageJ software.
Imaging of tumor sections
Frozen tumor tissues were sectioned at a thickness of
5 lm using a Vibratome UltraPro 5000 Cryostat.
Sections were mounted on microscope slides, dried in
air and washed with deionized water. Tumor sections
mounted on microscopic slides were directly incu-
bated with 1mM DAPI solution in PBS at 37 C for
about 10minutes and washed with PBS solution to
remove excess of the dye. Frozen tumor sections with
R18 contained pHLIPcoated niosomes were analyzed
without further processing using Zeiss LSM 700 con-
focal module under DAPI and Rhodamine channels
using a 20 objective lens. Following fluorescence
imaging, the adjacent sections were then stained with
hematoxylin and eosin (H&E) and imaged under
microscope.
Results
We introduced two formulations of pHLIP-coated
niosomes. In both cases the major components of
niosome content was Span20 (varied in the range of
43–45mol%) and cholesterol (50mol%) and in some
54 M. C. PEREIRA ET AL.
niosome formulations we also used fluorescent R18
(0–2mol%). pHLIP was conjugated either with DSPE
lipids (DSPE-pHLIP) or hydrophobic fluorescent dye,
pyrene, (Pyr-pHLIP) and introduced into niosomes at
amount of 5mol%. These formulations represent two
different approaches for introducing pHLIP into nio-
some coating: (i) pHLIP conjugated with the lipid
headgroup as it was done previously (Wijesinghe
et al., 2013) and (ii) pHLIP conjugated to various
hydrophobic molecules, such as pyrene, which have
high affinity to membrane and can intercalate into
bilayer. There is an advantage of using pyrene over
DSPE lipids, since (i) progression of conjugation reac-
tion of pHLIP with pyrene is easy to monitor by HPLC
and mass-spectrometry; (ii) incorporation of Pyr-pHLIP
into niosomes could be assessed by measuring
changes of pyrene fluorescence (see below) and (iii)
pyrene could be used for intercalation into bilayers of
various thicknesses.
The cryo-TEM imaging confirmed unilamellar struc-
ture of pHLIP-coated niosomes (Figure 1(a,b)). The
multiple cryo-TEM images were analyzed to plot size-
distribution histograms, which were fitted by Gauss
functions (Figure S2). The mean and standard devia-
tions of Gaussian distributions for DSPE-pHLIP and Pyr-
pHLIP coated niosomes were established to be 65.
2 ± 15.3 and 52.2 ± 10.1 nm, respectively (Table 1). The
hydrodynamic diameter of DSPE-pHLIP and Pyr-pHLIP
coated niosomes in solution were 89.7 ± 7.1 and 72.
6 ± 3.3 nm, respectively. The zeta potential of DSPE-
pHLIP and Pyr-pHLIP coated niosomes was 35.4m
and 31.3mV, respectively. When Pyr-pHLIP was
Figure 1. Cryogenic TEM image of the (a) DSPE-pHLIP (5mol%) , (b) Pyr-pHLIP (5mol%) coated Span20 (45mol%) and cholesterol
(50mol%) niosomes. The images are obtained at 25,000 magnification and (c) The fluorescence spectra of Pyr-pHLIP measured
in methanol and Pyr-pHLIP incorporated in niosomes.
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incorporated into niosomes the fluorescence spectra
of pyrene was altered compared to the pyrene emis-
sion in methanol (the niosome formulation used for
fluorescence measurements did not contain fluores-
cent R18) (Figure 1(c)). The appearance of the charac-
teristic excimer fluorescence at 440–500 nm was
observed, which indicates the stacking of pyrene rings
within the bilayer of niosomes.
We investigated shelf lifetime of pHLIP coated nio-
somes. The formulations were kept in buffer solution
of pH 7.4 refrigerated at 4 C for a month. The size of
particles remained unchanged in solution during
30 days, while the values of zeta potential decreased
on about 40% (from negative 30–35mV to negative
47–53mV) (Figure S3). The changes of zeta potential,
which were not associated with changes of particle
size, might be attributed to the oxidation of the
components of Span20 mixture forming negatively
charged species and enhancing an overall negative
charge of niosomes (de Sousa Lobato et al., 2013;
Kerwin, 2008; Kishore et al., 2011; Smith, 1981).
The cytotoxicity of the pHLIP-coated niosomes was
tested on murine 4T1 mammary cancer cells and
human lung A549 carcinoma cells. The data indicate
that DSPE-pHLIP and Pyr-pHLIP niosomes do not show
toxicity on cells. The pH-dependent cellular uptake of
the fluorescent pHLIP-coated niosomes containing
2mol% of R18 was assessed by quantifying rhodamine
fluorescence taken by the cells. Cells were treated with
R18 containing niosomes at pH 7.8 and pH 5.5 for
1 hour. We choose to treat cells with constructs at pH
7.8, which is slightly above than normal physiological
pH 7.4, since it was shown that pH at the surface of
cancer cells, especially highly metastatic cancer cells
such as 4T1, is lower even when pH of media is nor-
mal (Anderson et al., 2016). We also chose to treat
cells with constructs at pH 5.5, which is slightly lower
than mean pH 6.0 established at the surface of cancer
cells within tumors (Anderson et al., 2016) with the
main goal to enhance difference in cellular uptake of
niosomes in this model experiment. The fluorescent
signal from the cells treated with niosomes was ana-
lyzed using cellometer (Figure 2). We also used cell
impermeable dye, Trypan Blue, to quench fluorescent
signal outside of cells or at the outer leaflet of lipid
bilayer of plasma membrane to prove that fluorescent
Table 1. The center of Gauss distribution (DTEM) and the
standard deviation obtained after fitting of histograms of
niosome’s diameter distributions (shown on Figure S2) calcu-
lated by analyzing cryo-TEM images. The mean hydrodynamic
diameter (Dh), the zeta potential (n) and the polydispersity
index (PDI) were obtained from the dynamic light scattering
measurements performed on niosomes in HEPES buffer at pH
7.4. DSPE-pHLIP and Pyr-pHLIP (5mol%) coated Span20
(45mol%) and cholesterol (50mol%) niosomes were used.
Construct DTEM, nm Dh, nm n, mV PDI
DSPE-pHLIP 65.2 ± 15.3 89.7 ± 7.1 35.4 ± 2.3 0.19 ± 0.01
Pyr-pHLIP 52.2 ± 10.1 72.6 ± 3.3 31.3 ± 1.7 0.25 ± 0.01
Figure 2. Normalized uptake of DSPE-pHLIP (5mol%) and Pyr-pHLIP (5mol%) coated Span20 (43mol%) and cholesterol (50mol%)
niosomes containing 2mol% of fluorescent R18 by 4T1 mammary (a) and A549 lung (b) cancer cells at pH 7.8 and pH 5.5 before
(magenta columns) and after (gray columns) treatment with Trypan blue. The fluorescent signals were normalized by the rhoda-
mine fluorescence intensity of 4T1 cells at pH 7.8 treated with DSPE-pHLIP before addition of Trypan blue. Statistically significant
differences were determined by two-tailed unpaired Student’s t-test, only statistically non-significant differences are indicated (ns
means p level >0.05), all other differences in cellular uptake calculated at different pH’s, as well as before and after Trypan Blue
addition are statistically significant (plevel is less than 0.0001 in each case). The distribution of fluorescent signal in cells is pre-
sented in Figure S4.
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signal is associated with cellular uptake of niosomes. It
is known that Trypan Blue is used to quench fluores-
cence in the range of 580–620 nm (Nuutila & Lilius,
2005). The uptake of the fluorescent niosomes coated
with both DSPE-pHLIP and Pyr-pHLIP by 4T1 and A549
cancer cells was from 2–9 times higher at low pH com-
pared to the uptake at treatment pH of 7.8 (estab-
lished with high statistical significance, p-levels
determined by the two-tailed unpaired Student’s t-test
were less than 0.0001). Addition of Trypan Blue to cells
led to the quenching of rhodamine fluorescence. More
detailed information about cellular fluorescence after
the treatment with niosomes is presented in Figure S4.
Next, we investigated distribution of the fluorescent
niosomes within A549 and 4T1 cancer cells. Cells were
treated with R18 fluorescent niosomes at low pH (pH
6.4) for 1 hour, followed by washing, seeding cells in
glass bottom collagen coated cell dishes and imaging.
Figure 3. Uptake and cellular distribution of (a–d) DSPE-pHLIP (5mol%) and (e–h) Pyr-pHLIP (5mol%) coated Span20 (43mol%)
and cholesterol (50mol%) niosomes containing 2mol% of fluorescent R18 by A549 lung cancer cells. Cells were treated with fluor-
escence niosomes at pH 6.4 for 1 hour, followed by washing, seeding cells in glass bottom collagen coated cell dishes and imaging
at next day. Fluorescence (a, b, e, f) and phase contrast (c, d, g, h) images were obtained using 20 (a, c, e, g) and 40 (b, d, f,
h) magnification objective lenses.
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The fluorescent signal of DSPE-pHLIP and Pyr-pHLIP
coated niosomes in A549 cells (Figure 3) and 4T1 cells
(Figure S5) were distributed through cells, most prob-
ably in endosomes and lysosomes. The data confirmed
pH-dependent cellular uptake of pHLIP-coated
niosomes.
Finally, our goal was to investigate tumor targeting
and distribution of pHLIP-coated niosomes, which we
compared with the control niosomes coated with PEG
polymer that accumulate in tumors due to the EPR
effect. Before proceeding to animal studies we
investigated the stability of pHLIP and PEG coated nio-
some formulations in plasma and calculated percent-
age of hemolysis. RBCs and plasma were separated
from human blood samples. RBCs were treated with
two sets of increasing concentrations of pHLIP and
PEG coated niosomes with and without R18 for 2 hours
at 37 C. The lysis of RBCs was less than 1% in the
case of use of DSPE-pHLIP and Pyr-pHLIP coated nio-
somes and less than 2% for DSPE-PEG coated nio-
somes. Also, stability of pHLIP and PEG coated
niosomes with and without R18 were investigated for
Figure 4. Time-dependent distribution of DSPE-pHLIP and Pyr-pHLIP (5mol%), Span20 (43mol%), cholesterol (50mol%) and R18
(2mol%) niosomes in a) tumor, b) muscle, c) kidney and d) liver at 4, 24 and 48 hours after single I.V. administration of the
constructs. Tumor/Muscle (T/M), Tumor/Kidney (T/K) and Tumor/Liver (T/L) ratio calculated for DSPE-pHLIP (e) and Pyr-pHLIP (f) nia-
somes are shown. The values of mean surface fluorescence intensity of R18 in tissue and organs are presented in Table S1.
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24 hours in plasma separated from the blood. The size
of all niosome formulations (DSPE-pHLIP, Pyr-pHLIP
and DSPE-PEG) was not altered indicating on their sta-
bility in blood.
The tumor targeting of the fluorescent R18 contain-
ing DSPE-pHLIP and Pyr-pHLIP coated niosomes were
investigated in mice. Fluorescent niosomes were given
as a single tail vein injection, animals were euthanized
at different time points post-injection (4, 24 and
48 hours). Main organs were collected, cut in half and
imaged (Figure 4 and Table S1). At 24 hours we
observed peak in tumor uptake of the fluorescent nio-
somes. The mean tumor to muscle ratio within
48 hours was found to be 4.9 ± 1.3 and 6.8 ± 1.4 nm for
DSPE-pHLIP and Pyr-pHLIP coated niosomes, respect-
ively. The signal in kidney was minimal, with some
accumulation of the constructs in liver. Uptake of
pHLIP-coated niosomes by tumor, muscle, kidney and
liver at 24 hours post-injection was compared with the
uptake of PEG-coated niosomes. Figure 5(a) shows rep-
resentative images of tumor and organs obtained from
mice injected with different constructs and Figure 5(b)
(and Table S2) reflects quantitative uptake of the con-
structs by the tumors and organs. Tumor-targeting
niosomes coated with pHLIP exhibited 2.1–2.7 times
higher tumor uptake compared to the non-targeted
niosomes coated with PEG polymer. Figure 6
demonstrates cellular distribution of fluorescent signal
within the tumor mass. The sections were obtained
from the center of the tumors. The fluorescence is
associated with cellular structures and no nuclear
staining was observed as in the case of experiments
on cultured cells.
Discussion
The targeted delivery of nanomaterials is one of the
most important aspects of successful development of
nanotechnology and translation of nanomaterials to
the clinics. Various approaches are tested with moder-
ate success. Our approach is based on targeting of
tumor acidity by utilizing ability of pHLIPs to sense pH
at the surface of cells. Acidosis is a general property of
tumor micro environment associated with tumor
development and progressions (Fang et al., 2008;
Gillies et al., 2008; Vander Heiden et al., 2009).
Moreover, acidity is linked to other pathological states,
such as ischemia, atherosclerosis, stroke (Koo et al.,
1993; Mizock & Falk, 1992; Rajam€aki et al., 2013). It
was shown that nanoparticles coated with pHLIP pro-
mote targeting and cellular uptake of these nanopar-
ticles (Emmetiere et al., 2013; Han et al., 2013; Janic
et al., 2016; Tian et al., 2017; Wei et al., 2017;
Wijesinghe et al., 2013; Yao et al., 2013a, 2013b;
Figure 5. (a) The representative rhodamine fluorescence images and (b) mean surface fluorescence of tumor (cut in half ), muscle,
kidney (cut in half) and liver obtained by ex vivo imaging after collection of organs and tissues 24 hours after I.V. administration of
pHLIP and PEG coated niosomes are shown (the autofluorescence signal is subtracted). The color coded fluorescent images shown
on panel (a) are obtained at the same settings of the imaging instrument, the same exposure time (15 sec) and all of them were
processed exactly the same way. Control is the organs collected from the mouse with no injection of fluorescent niosomes and it
represents level of auto fluorescence signals in tissue. The values of mean surface fluorescence intensity of R18 in tissue and
organs are presented in Table S2.
MOLECULAR MEMBRANE BIOLOGY 59
Figure 6. Distribution of R18 fluorescent signal in tumor sections obtained at 24 hours after I.V. injection of (a–d) DSPE-pHLIP
(5mol%) and e–h) Pyr-pHLIP (5mol%) coated Span20 (43mol%), cholesterol (50mol%) and R18 (2mol%) niosomes. The rhoda-
mine fluorescence (a, e), cell nucleus stained with DAPI (b, f), the overlay of rhodamine and DAPI fluorescence (c, g), and adjacent
HE stained sections from the same tumor (d, h) are shown.
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Yu et al., 2015, 2016). Previously, we demonstrated
that pHLIP-coated liposomes are capable to fuse with
cellular membranes and promote delivery hydrophobic
cargo molecules to cellular membranes and hydro-
philic payloads to cytoplasm of cancer cells (Yao et al.,
2013b). In this work we tested surfactant- and choles-
terol-based niosomes. The pHLIP-coated niosomes
were smaller in size and more stable compared to the
pHLIP-coated liposomes. pHLIP-coated niosomes dem-
onstrated pH-dependent cellular uptake and excellent
tumor targeting. Control non-targeted PEG-coated nio-
somes exhibited 2–3 times less tumor accumulation.
Targeting of acidic tumors occurs due to the ability of
pHLIPs to insert into cellular membranes in environ-
ment of low extracellular pH. Thus, at low pH pHLIPs
behave as fusogenic peptides, which bring the nio-
some membrane in close contact to the cellular mem-
brane. These are the two main possibilities of pHLIP-
coated niosome’s cellular entry. Either pHLIP-coated
niosomes might fuse directly with the plasma mem-
brane of cancer cells in environment of low pH and/or
niosomes can be taken up into the cell via endocytotic
pathways, more favorably, via micropinocytosis due
simultaneous insertions of multiple pHLIPs into the
cellular membrane. Niosomes, which are internalized
into cell via endocytosis might fuse with the endoso-
mal membrane at low pH. In either case, niosomes car-
rying lipophilic and/or hydrophilic drugs can
effectively enter into the cells in a pH-dependent
manner.
The pHLIP-coated liposomes and niosomes follow a
closely similar mechanism utilized by viruses and
pathogenic organisms to enter into a cell. In contrast
to liposomes, niosomes are smaller in size, they dem-
onstrate prolong shelf life, very good tumor targeting
and distribution within tumor and their manufacturing
cost is lower. On other hand, niosome’s encapsulation
capacity is lower and different combinations of surfac-
tants are needed for entrapment of various hydropho-
bic molecules within their bilayer to preserve overall
stability of nano-vesicles. Different formulations might
find utility for different therapeutic purposes.
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